We provide you with 20 years of free, institutional-grade data for BCYC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BCYC. Explore the full financial landscape of BCYC stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Thompson Travis Alvin | Sale | -901 | $4.91 | $4,424 | 2026-04-06 |
| Perry Jennifer Scott | Sale | -1,408 | $4.91 | $6,913 | 2026-04-06 |
| Lee Kevin | Sale | -7,683 | $4.91 | $37,724 | 2026-04-06 |
| Skynner Michael | Sale | -2,404 | $4.91 | $11,804 | 2026-04-06 |
| Hannay Michael Charles Ferguson | Sale | -1,772 | $4.91 | $8,701 | 2026-04-06 |
| Perry Jennifer Scott | Initial | 2026-03-25 | |||
| Skynner Michael | Sale | -6,311 | $6.8 | $42,915 | 2026-01-06 |
| Skynner Michael | Grant, award...etc | 50,000 | 2026-01-06 | ||
| Hannay Michael Charles Ferguson | Sale | -5,194 | $6.8 | $35,319 | 2026-01-06 |
| Hannay Michael Charles Ferguson | Grant, award...etc | 50,000 | 2026-01-06 | ||
| Milnes Alistair | Sale | -6,660 | $6.8 | $45,288 | 2026-01-06 |
| Milnes Alistair | Grant, award...etc | 50,000 | 2026-01-06 | ||
| Young Alethia | Sale | -7,623 | $6.8 | $51,836 | 2026-01-06 |
| Young Alethia | Grant, award...etc | 50,000 | 2026-01-06 | ||
| Lee Kevin | Sale | -21,314 | $6.8 | $144,935 | 2026-01-06 |
| Lee Kevin | Grant, award...etc | 165,000 | 2026-01-06 | ||
| Young Alethia | Sale | -482 | $8.4 | $4,049 | 2025-10-06 |
| Thompson Travis Alvin | Sale | -324 | $8.4 | $2,722 | 2025-10-06 |
| Swanton Robert Charles | Sale | -102 | $8.55 | $872 | 2025-10-06 |
| Hannay Michael Charles Ferguson | Sale | -723 | $8.4 | $6,073 | 2025-10-06 |
| Milnes Alistair | Sale | -2,125 | $8.4 | $17,850 | 2025-10-06 |
| Skynner Michael | Sale | -1,802 | $8.4 | $15,137 | 2025-10-06 |
| Lee Kevin | Sale | -5,494 | $8.4 | $46,150 | 2025-10-06 |
| Hoppenot Herve | Grant, award...etc | 12,500 | 2025-09-10 | ||
| DANSEY ROGER D | Grant, award...etc | 12,500 | 2025-09-10 |
The information provided in this report about BCYC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Bicycle Therapeutics plc(NASDAQ:BCYC) 
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express...
Website: http://bicycletherapeutics.com
Founded: 2009
IPO Price: $14 (May 23, 2019)
Full Time Employees: 81
CEO: Kevin Lee
Sector: Healthcare
Industry: Biotechnology